Drug intelligence / Profile preview

Debio 1142

Development stage: Discontinued
Lead developer: Debiopharm
Modality: Small Molecules
Administration: Oral

Overview

Debio 1142 is an orally available small‑molecule oncology candidate from Debiopharm, discovered in collaboration with Aurigene, and described as a novel inhibitor of an undisclosed cancer pathway that plays key roles in solid tumors and resistance to chemotherapy.[3][6][7][10][13] Public information characterizes it as part of a Debiopharm–Aurigene research program in cancer therapeutics, with preclinical development reported in Switzerland and India but with no subsequent clinical development or disclosed target, suggesting that the compound has remained an early‑stage investigational asset.[3][7][10][13]

Beyond the preview

Go deeper on Debio 1142.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Debio 1142.

Explore the full profile